Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare gene defect may fuel liver cancer in otherwise healthy livers

NCT ID NCT07145385

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find out how often a rare genetic condition called alpha-1 antitrypsin deficiency (AATD) occurs in people who develop liver cancer (hepatocellular carcinoma) but do not have cirrhosis or other known causes like hepatitis or heavy drinking. Researchers will look back at medical records of 71 adults with this type of liver cancer to see if AATD is a hidden risk factor. The results could help identify a new cause for some liver cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 71 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients Diagnosed with HCC on non-cirrhotic liver

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (≥18 years of age). 2. Histopathologically confirmed diagnosis of hepatocellular carcinoma (HCC). 3. Normal liver or chronic liver disease with minimal to moderate fibrosis in non-tumoral tissue. 4. Signed informed consent obtained prior to participation. 5. No other known etiology or risk factors for liver disease, including: * Alcohol-related liver disease * Metabolic-associated steatohepatitis (MASH) * Viral hepatitis infections * Hemochromatosis Exclusion Criteria: 1. Minor patients (\<18 years of age). 2. HCC diagnosis not established according to standard histopathological criteria. 3. Liver with chronic liver disease showing advanced fibrosis in non-tumoral tissue. 4. No signed informed consent prior to participation. 5. Presence of other identified etiologies or known risk factors for liver disease, including: * Alcohol-related liver disease * Metabolic-associated steatohepatitis (MASH) * Viral hepatitis infections * Hemochromatosi

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retrospective cohort of patients diagnosed with HCC on non-cirrhotic liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retrospective cohort of patients diagnosed with HCC on non-cirrhotic liver

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France